Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Soleno Therapeutics Inc maintains a gross margin of 99.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 44.08%, while the net margin is 47.27%. These profitability ratios, combined with a Return on Equity (ROE) of 5.89%, provide a clear picture of how effectively SLNO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SLNO competes directly with industry leaders such as HROW and OCUL. With a market capitalization of $2.02B, it holds a significant position in the sector. When comparing efficiency, SLNO's gross margin of 99.06% stands against HROW's 79.27% and OCUL's 87.97%. Such benchmarking helps identify whether Soleno Therapeutics Inc is trading at a premium or discount relative to its financial performance.
